CD30/TNFRSF8[Biotin], His & Avi, Human
¥5800 | |
Z04063-100 | |
|
|
|
|
|
¥5800 | |
Z04063-100 | |
|
|
|
|
|
Species | Human | ||||||
Protein Construction |
|
||||||
Conjugate | Biotin | ||||||
Purity |
> 95% as determined by BisTris PAGE > 95% as determined by HPLC |
||||||
Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||||
Biological Activity | Measured by its binding ability in a functional ELISA. Immobilized Human CD30 Ligand, His Tag at 5μg/ml (100μl/well) on the plate can bind CD30/TNFRSF8[Biotin], His & Avi, Human. Test result was comparable to standard batch | ||||||
Expression System | HEK293 | ||||||
Theoretical Molecular Weight | 41.3 kDa | ||||||
Apparent Molecular Weight | Due to glycosylation, the protein migrates to 70-100 kDa based on Bis-Tris PAGE result. | ||||||
Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||||
Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||||
Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
Immobilized Human CD30 Ligand, His Tag at 5 μg/ml (100 μL/well) on the plate. Dose response curve for CD30/TNFRSF8[Biotin], His & Avi, Human, His Tag with the EC50 of 17.5 ng/ml determined by ELISA. »
The purity of CD30/TNFRSF8[Biotin], His & Avi, Human is greater than 95% as determined by SEC-HPLC. »
CD30/TNFRSF8[Biotin], His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
Immobilized Anti-CD30 Antibody, hFc Tag at 0.5 μg/ml (100 μl/well) on the plate. Dose response curve for CD30/TNFRSF8[Biotin], His & Avi, Human, His Tag with the EC50 of 10.8 ng/ml determined by ELISA. »
Target Background | The transmembrane receptor CD30 (TNFRSF8) and its ligand CD30L (CD153, TNFSF8) are members of the tumor necrosis factor (TNF) superfamily and display restricted expression in subpopulations of activated T-and B-cells in nonpathologic conditions. CD30 expression is upregulated in various hematological malignancies, including Reed-Sternberg cells in Hodgkin's disease (HD), anaplastic large cell lymphoma (ALCL) and subsets of Non-Hodgkin's lymphomas (NHLs). |
Synonyms | CD30; CD30KI-1; CD30L receptor; TNFRSF8; D1S166EKi-1; CD30KI-1 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.